Israel, and just the other day Hong Kong, has now approved the Alzheimer's drug Leqembi for use, which the USA, Japan, South Korea, and China have done previously. This is stated by the Swedish pharmaceutical company Bioarctic in a press release.
Approval for Europe is still pending, but the European Medicines Agency EMA is in the final phase of its review, as Dagens Industri recently reported.
Leqembi is being developed by American Biogen and Japanese Eisai, but is based on a discovery by Bioarctic.
